July 26, 2010 — The US Food and Drug Administration (FDA) has approved the first generic formulation of enoxaparin sodium injection (Sandoz, Inc; brand name, Lovenox; Sanofi-Aventis US, LLC), a ...

(RTTNews) - Sandoz, Inc., an unit of Novartis Pharma AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high ...

Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion ...

Zydus has signed a license and supply agreement with Chemi of Italy, a subsidiary of Italfarmaco Group, to launch the generic of Sanofi Aventis’s Lovenox (enoxaparin sodium injection) in seven dosage ...

A steamy shipping glitch has forced Novartis' generics unit to yank a batch of deep vein thrombosis meds from U.S. shelves. Sandoz is recalling one lot of enoxaparin sodium injection single-dose ...

Techdow USA Inc., a division of the Hepalink Group (Techdow USA), has announced its next finished drug product launch, Enoxaparin Sodium (Enoxaparin). This product is expected to launch in June of ...

CHICAGO, April 19 (Reuters) - Paralysed stroke patients, who are at risk of a second blood clot, are helped more by a blood thinner made by Sanofi-Aventis than an older, cheaper drug, according to a ...

LONDON (Reuters) - Bayer AG has launched its new anticoagulant pill Xarelto in Britain and Germany, pricing the product on a par with Sanofi-Aventis's Lovenox injection, the company said on Thursday.

Emphasizing the tenet that antitrust laws are enacted to protect ­competition—and not competitors—the Third Circuit has rejected one competitor's claim that Sanofi-Aventis had an unfair advantage in ...

Watson Pharmaceuticals, Inc. confirmed that the United States District Court for the District of Massachusetts has granted a request by Momenta Pharmaceuticals, Inc. and Sandoz Inc. for a temporary ...

The sidebar on the pooled analysis of RECORD1, 2, and 3 has been added to this story, which was originally published June 23, 2008. Rivaroxaban is one of several potential new oral anticoagulants in ...